Gbio

What Gbio does

Gbio Farmacêutica is a Brazilian specialty pharmaceutical company focused exclusively on ocular health, operating as the ophthalmology-dedicated subsidiary of Grupo Geolab, which is ranked 2nd among Brazil's top 30 pharmaceutical companies by unit sales. The company develops, manufactures, and markets a portfolio of 17 ophthalmic products organized into six therapeutic categories: eyelid hygiene (Hiluropt Clean), artificial tears (Hiluropt, Hiluropt Max, Sensilacri, Tearfilm), anti-glaucoma medications (Xalanoft, Xaloftal, Bimagan, Travoptic, Alphabrin, Visoptic), anti-inflammatory ophthalmics (Visiopred, Optilar), antibiotic treatments (Oftalmox, Duodex), and nutritional supplements for eye health (Reluze, Tearcaps). Products are delivered in multiple dosage forms — ophthalmic solutions, emulsions, capsules, and ointments — built on established active ingredients (sodium hyaluronate, dextran/hypromellose, prostaglandin analogs, omega-3 fatty acids, lutein/zeaxanthin) rather than proprietary novel compounds. Two manufacturing facilities in Anápolis, Goiás, totaling approximately 92,000 m² and situated within one of Latin America's largest pharmaceutical hubs, supply the line under ISO 14001 environmental certification.

The commercial model combines a sales-led B2B motion with broad direct-to-consumer reach. Gbio generates revenue through pharmaceutical product sales to end consumers via a network of 18 major Brazilian pharmacy chains (including Droga Raia, Drogaria São Paulo, Pague Menos, Panvel, Drogasil, and Araujo), supported by a field propagandist network that engages ophthalmologists and eye-care physicians, and a direct-to-consumer channel via WhatsApp and a toll-free SAC. Pricing is managed through pharmacies and is not publicly disclosed. Brand authority is reinforced through an extensive educational content library on gbio.com.br covering ocular health topics and a strategic partnership with the Sociedade Brasileira de Glaucoma (SBG) for medical-society-backed awareness.

Founded as part of Grupo Geolab in 1998 and headquartered in São Paulo (Berrini district) with manufacturing in Anápolis, Gbio operates exclusively in the Brazilian market. The company has no disclosed revenue, no public listing, no recorded funding rounds, and no M&A activity in the input data; ownership sits entirely with the Geolab parent group.

Name

Gbio

Legal name

Gbio Farmacêutica

Website

https://gbio.com.br

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

1–10 employees

Short description

Gbio Farmacêutica is a Brazilian specialty pharmaceutical company that develops and markets 17 ophthalmic products — including artificial tears, anti-glaucoma, anti-inflammatory, antibiotic, and ocular-nutrition lines — distributed through 18 national pharmacy chains and a physician sales network, serving eye-care patients and ophthalmologists across Brazil.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Ophthalmic Goods Manufacturing (339115)

SIC

Pharmaceutical Preparations (2834), Ophthalmic Goods (3851)

akta.pro primary industry

Ophthalmology Pharmaceuticals (HLAIAAAL)

akta.pro secondary industry

Ophthalmic & Otic Generics (HLAIABAF)

Keywords

• Ophthalmic pharmaceuticals
• Artificial tears
• Anti-glaucoma medications
• Ocular health supplements
• Eye care products

Headquarters

HQ city

São Paulo

HQ country

Brazil

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Gbio generates revenue through the manufacture and sale of prescription and OTC ophthalmic pharmaceutical products across six categories: eyelid hygiene, artificial tears, anti-glaucomatous, anti-inflammatory, antibiotics, and supplements. Products are distributed through a network of major Brazilian pharmacy chains.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Gbio Farmacêutica manufactures and distributes a portfolio of ophthalmic pharmaceutical products across six therapeutic categories: eyelid hygiene (Hiluropt Clean), artificial tears (Hiluropt, Hiluropt Max, Sensilacri, Tearfilm), anti-glaucomatous medications (Xalanoft, Xaloftal, Bimagan, Travoptic, Alphabrin, Visoptic), anti-inflammatory treatments (Visiopred, Optilar), antibiotics (Oftalmox, Duodex), and ocular nutritional supplements (Reluze, Tearcaps). Products are sold through major Brazilian pharmacy chains and physician-directed sales channels, addressing conditions including dry eye, glaucoma, inflammation, eye infections, and eyelid hygiene.

Product overview

Gbio is a pharmaceutical company specializing in ocular health, operating as part of Grupo Geolab. The company offers a comprehensive portfolio of 17 ophthalmological products across six therapeutic categories: eyelid hygiene (Hiluropt® Clean), artificial tears (Hiluropt, Hiluropt Max, Sensilacri, Tearfilm), anti-glaucoma medications (Xalanoft, Xaloftal, Bimagan, Travoptic, Alphabrin 1mg/mL, Alphabrin 2mg/mL, Visoptic), anti-inflammatory ophthalmics (Visiopred, Optilar 4mg/mL, Optilar 5mg/mL), antibiotic treatments (Oftalmox, Duodex), and nutritional supplements for eye health (Reluze, Tearcaps). The product line serves both adult and pediatric populations, addressing conditions from dry eye and eyelid hygiene to glaucoma and inflammation.

Differentiator

Problem solved

Functional benefit

Products and services

• Hiluropt Clean Eyelid hygiene solution for cleaning eyelids and eyelashes, for adult and pediatric ophthalmic use.
• Hiluropt Sodium hyaluronate ophthalmic solution 1.5 mg/mL (0.15%) for lubricating and hydrating the eye surface, presented in 10 mL dropper bottle for adult ophthalmic use.
• Hiluropt Max Sodium hyaluronate ophthalmic solution 2.0 mg/mL (0.20%) with higher viscosity for enhanced eye surface protection and hydration.
• Sensilacri Dextran + Hypromellose ophthalmic solution at 1 mg/mL + 3 mg/mL concentrations, presented in 15 mL dropper bottle for adult and pediatric use.
• Tearfilm Artificial tear product for ocular lubrication.
• Xalanoft Anti-glaucomatous ophthalmic medication.
• Xaloftal Anti-glaucomatous ophthalmic medication.
• Bimagan Anti-glaucomatous ophthalmic medication.
• Travoptic Anti-glaucomatous ophthalmic medication.
• Alphabrin 1mg/mL Anti-glaucomatous ophthalmic solution at 1mg/mL concentration.
• Alphabrin 2mg/mL Anti-glaucomatous ophthalmic solution at 2mg/mL concentration.
• Visoptic Anti-glaucomatous ophthalmic medication.
• Visiopred Anti-inflammatory ophthalmic medication for treating ocular inflammation.
• Optilar 5mg/mL Anti-inflammatory ophthalmic solution at 5mg/mL concentration.
• Optilar 4mg/mL Anti-inflammatory ophthalmic solution at 4mg/mL concentration.
• Oftalmox Antibiotic ophthalmic medication for treating eye infections.
• Duodex Antibiotic ophthalmic medication.
• Reluze Oral nutritional supplement in capsule form containing lutein, zeaxanthin, vitamins C and E, calcium and zinc with antioxidant properties for maintaining ocular health. Contains 60 capsules, sugar-free and gluten-free, recommended dose is 2 capsules once daily.
• Tearcaps Oral supplement with Omega 3 (TG form), vitamins and minerals formulated specifically to relieve dry eye symptoms.

Named customers18 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Sociedade Brasileira de Glaucoma (SBG)coreStrategic or Co-development Partner · 1 May 2026Gbio partnered with the Brazilian Glaucoma Society (SBG) to strengthen its commitment to disseminating reliable information, ocular health education, and awareness about the importance of early glaucoma diagnosis. The partnership aligns Gbio's mission with the SBG's medical expertise.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Alcon: Global leader dedicated to eye care, offering a broad ophthalmic pharmaceutical portfolio (including glaucoma and dry eye treatments) that competes directly with Gbio's product categories across international markets. Alcon's surgical and pharmaceutical divisions overlap with Gbio's anti-glaucoma and artificial tear lines.
• EMS: One of Brazil's largest pharmaceutical manufacturers with a meaningful ophthalmology portfolio, competing head-to-head with Gbio in Brazilian pharmacy chains across generics and branded generics.
• Eurofarma: Brazilian pharmaceutical company with operations across multiple therapeutic areas including ophthalmology, competing with Gbio in pharmacy retail channels and physician promotion.
• Bausch + Lomb: Diversified eye health company with a meaningful ophthalmic pharmaceuticals portfolio (including glaucoma, dry eye, and anti-inflammatory products) directly overlapping Gbio's six therapeutic categories.
• Allergan (AbbVie): Major ophthalmology pharmaceutical player with brands such as Lumigan (bimatoprost) and Refresh artificial tears — directly competing with Gbio's Bimagan, Hiluropt, and Travoptic lines on the same molecules and therapeutic categories.
• Cristália: Brazilian pharmaceutical manufacturer with both branded and generic ophthalmic products, overlapping Gbio's portfolio in glaucoma, anti-inflammatories, and ocular lubricants.
• Aché Laboratórios: Major Brazilian pharmaceutical company with an established ophthalmology franchise, comparable to Gbio in its combination of branded generics, retail distribution scale, and physician-focused sales force.

Emerging players

• Sun Pharma: Global generics powerhouse with an ophthalmology specialty business; competes with Gbio primarily through cost-driven generic molecules that overlap with Gbio's off-patent portfolio.

Broad incumbents

• Novartis (Ophthalmology): Originator of latanoprost (Xalatan), the molecule behind Gbio's Xalanoft. Novartis operates broadly across pharma but its ophthalmology division is a direct benchmark for prescription glaucoma product strategy and pricing.
• Pfizer Ophthalmology: Global pharmaceutical incumbent with ophthalmology products (including historical Xalatan franchise); serves as a benchmark for branded originator pricing pressure facing Gbio's generic-equivalent portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gbio

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gbio